excluding paroxysmal nocturnal hemoglobinuria. Several months after initial detection, the anti-IFC was virtually undetectable and his cells reacted weakly with anti-IFC, anti-Dr a , and anti-CD55. RBCs from the propositus' parents and brother demonstrated normal CD55 and CD59 expression. CONCLUSION: This is the first example of a directagglutinating anti-IFC. The cause of the transient depression in CD55 protein (and thus Cromer system antigens) and appearance of anti-IFC remains unknown, as does the relationship between the patient's GI system abnormalities and these serologic findings.
here are 14 antigens in the Cromer blood group system, 11 of high incidence and three of low incidence (Table 1) . [1] [2] [3] [4] [5] [6] All of these antigens are located on the complement regulating protein decay-accelerating factor (DAF, CD55), which is tethered to the red blood cell (RBC) membrane by a glycosylphosphatidylinositol (GPI) anchor. 7 There are three molecular backgrounds that give rise to weakened or absent expression of Cromer antigens. First, somatic mutations in the X-linked phosphatidylinositol-glycan-complementation class A (PIG-A) gene result in a biosynthetic defect in GPI anchor synthesis and hence the absence of all GPI-linked proteins on the RBC surface. 8 The absence or reduction of these proteins on RBCs occurs in paroxysmal nocturnal hemoglobinuria (PNH). In its most extreme form, when the two main regulators of complement, CD55 and membrane inhibitor of reactive lysis (CD59) are completely lacking on the RBC surface; intravascular hemolysis occurs and has been associated with thrombosis (reviewed in Rosse and Nishimura 9 ). Second, reduced Cromer system antigen expression occurs in the case of the rare Dr(a-) RBCs. 10 The molecular basis for this phenotype is a single-nucleotide polymor-T phism (SNP) in exon 5 of DAF, 596C>T, which results in alternative splicing of the DAF mRNA such that the resulting major transcript lacks 44 nucleotides. [10] [11] [12] In addition, this alternative splicing shifts the reading frame and introduces a premature stop codon; the translated protein cannot attach to the membrane and is not present on the membrane of the RBCs. 12 A small minority of the DAF mRNA transcripts, however, contain this SNP but do not utilize the cryptic splice acceptor site. 13 These minor transcripts are translated normally with the result that there is a reduced copy number of CD55 and weakened expression of Cromer system antigens on Dr(a-) cells. 13 Third, Inab phenotype RBCs, named after the original Japanese propositus, lack all Cromer system antigens. 14 This rare phenotype has been previously reported in nine people and is typically recognized by the presence of an alloantibody (anti-IFC) in their serum to a high-incidence antigen of the Cromer system absent on these cells (Table 2) . [14] [15] [16] [17] [18] [19] [20] Several SNPs have been identified underlying this phenotype. The original Japanese propositus 14 and another unrelated Japanese individual 18 demonstrated a nonsense 261G>A polymorphism in exon 2 of the DAF gene rendering the protein unable to be tethered to the GPI anchor. Two Japanese individuals with the Inab phenotype were reported to have a different SNP, 263C>A, which causes a 26-bp deletion in the DAF mRNA secondary to the activation of a cryptic splice site. 17, 19 Recently, another Japanese proband with the Inab phenotype and a novel nonsense SNP (508C>T, Arg136Stop) was identified. 20 The molecular basis for the Inab phenotype in several patients of Jewish, 15 Italian, 16 and African American 18 descent has not been elucidated. Curiously, some of the first patients with the Inab phenotype were noted to have a variety of gastrointestinal (GI) system abnormalities, whereas others with the Inab phenotype lacked these problems ( Table 2 ). In addition, there are two reports of transient IFCnegative individuals. One was a previously healthy Kenyan national with HbS trait, unexplained splenic infarcts, and transient Inab phenotype. 21 The patient had no GI abnormalities and had never received a transfusion, yet an anti-IFC-reactive at indirect antiglobulin test (IAT) was present in his serum sample, and his cells were clearly lacking CD55 by flow cytometric analysis. 21 More recently, an elderly female patient with chronic lymphocytic leukemia and transient Inab phenotype with anti-IFC was reported. 22 We report another example of a patient with transient Inab phenotype, who unlike the previous transient Inab phenotype propositi, had GI abnormalities and a direct agglutinating anti-IFC.
CASE REPORT
The propositus is a Caucasian male born at 38 weeks' gestation with congenital cytomegalovirus disease causing blindness and deafness. The patient had severe growth retardation (height, first percentile; weight, 0 percentile) and suffered significant gastroesophageal reflux disease as well as milk and soy 
MATERIALS AND METHODS

RBC serology
Standard serologic techniques were performed throughout this case study investigation. 23 Reagent RBCs and antibodies to blood group antigens were from either ImmucorGamma (Norcross, GA) or Ortho Clinical Diagnostics (Raritan, NJ), or from the private collections of our institutions. Gel column technology was from Ortho Clinical Diagnostics.
Immunoglobulin G (IgG) monoclonal antibodies to CD55 and CD59 were a gift from G. Halverson of the Lindsay F. Kimball Research Institute at the New York Blood Center and were tested against RBCs in gel columns containing mouse anti-IgG (MicroTyping Systems, Pompano Beach, FL). Escherichia coli (E. coli 12F), containing the 075X adhesin (Dr a adhesin), 24 was a gift from C.F. Marrs (School of Public Health, University of Michigan). Bacterial hemagglutination tests were performed on buffered gel cards (Ortho Clinical Diagnostics) as described previously.
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Flow cytometry
Washed RBCs (50 µL, 3% suspension) were incubated with IgG monoclonal anti-CD55 and CD59 (50 µL) for 30 minutes at room temperature. After being washed, the RBCs were incubated with fluorescein isothiocyanate (FITC)-labeled mouse anti-IgG, washed, and then resuspended in 500 µL of phosphate-buffered saline-1 percent paraformaldehyde. After fixation, cells were analyzed by one-color flow cytometry (FACScan, Becton Dickinson, Hialeah, FL) with the accompanying software (Cell-Quest, Becton Dickinson). Cells were gated on forward and orthogonal scatter, and the percentage FITC-positive cells was determined. All samples were stained in duplicate and recorded as the mean percent positive cells and mean channel fluorescence.
Sequencing of DNA
Genomic DNA was isolated from whole blood (QIAamp blood kit, Qiagen, Inc., Valencia, CA). The regions of DAF that include and flank exon 2, exon 3, exon 4, exon 5, and exon 6 (which encode SCRs 1-4) were individually amplified with sets of primers derived from Banks and colleagues 4 and Telen and coworkers 26 with modified primers DAFSCR2R (GAGTTCTAGCATGAATGAAGGAAGGG) and DAFSCR4F (GCATCTCTTGTTGGTAATGCTGG). The primers were synthesized by Life Technologies, Inc. (Gaithersburg, MD). Two microliters of DNA per reaction was amplified by 5 U Taq DNA polymerase (HotStarTaq, Qiagen) in a 50-µL reaction mixture containing 2.0 mmol per L MgCl 2 (1.5 mmol/L MgCl 2 for exon 2 primers), 1× PCR buffer, 0.2 mmol per L dNTPs, and 100 ng of forward and reverse primer. Amplification was achieved over 35 cycles with a final extension time of 10 minutes. The PCR products were sequenced directly in the Laboratory of Microchemistry at the New York Blood Center with an automated DNA sequencer (ABI 373XL, Applied Biosystems, Inc., Foster City, CA), and reagents (ABI Big Dye reagents with BD Half-Term, GenPak, Stony Brook, NY). The PCR products were sequenced in both directions. adhesin. 25 Overall, in view of the IFC-negative phenotype of the propositus, this antibody is considered to have anti-IFC specificity, although typically anti-IFC would be expected to react weakly with Dr(a-) RBCs.
RESULTS
Serology
October 2004. The antibody detecting a high-prevalence antigen of the Cromer blood group system was virtually undetectable in his serum sample; it reacted only microscopically by albumin IAT with one of six panel cells tested and also with a cord RBC sample. The propositus' plasma also reacted weakly at room temperature with four of seven RBC samples suspended in saline. As before, the patient's RBCs were negative in the DAT, but his RBC phenotype had changed such that his cells were now weakly reactive with anti-Dr a and anti-IFC. His RBCs still failed to be agglutinated by E. coli 12F. Weak reactivity was now observed when his cells were tested with monoclonal anti-CD55 by mouse anti-IgG gel cards. At this time the RBCs of his mother, father, and brother were also obtained and evaluated for the expression of CD55; these family members demonstrated normal expression of CD55.
Flow cytometry
CD55 was virtually absent from the RBCs of the propositus in August (gated events, 1.6 percent of control; Fig. 1 ). However, in October the number of CD55-positive cells (gated events) had increased to 28 percent of control. CD59 was expressed normally in specimens from both dates. This finding, taken together with the presence of the GPIanchored Yt a and Emm antigens on his RBCs, excludes PNH as the cause of reduced CD55 expression. The levels of CD55 and CD59 were also evaluated on RBCs from his parents and his brother in October: as in agglutination-based studies, RBCs of these family members demonstrated normal CD55 and CD59 expression.
Sequencing of DNA
Exons 2 through 6 of DAF and their flanking intronic sequences were sequenced and found to be identical to the consensus sequence.
DISCUSSION
This is the first report of a patient with the triad of GI abnormalities, transient Inab phenotype, and a direct agglutinating antibody directed at a high-prevalence Cromer antigen. The specificity is considered to be anti-IFC based on the findings that the patient's RBCs were IFC-and that the antibody did not agglutinate IFC-or Dr(a-) RBCs. The failure to agglutinate Dr(a-) RBCs is most likely due to the very low levels of Cromer antigens expressed on RBCs with this phenotype. Unlike a previous case report of a patient with transient Inab phenotype with anti-IFC, 21 our patient did not manifest thrombotic complications, although in both cases a generalized absence of GPI-linked proteins was excluded by the presence of normal amounts of CD59 on the RBC surface. Exons 2 through 6 of DAF were consensus in both propositi. Unfortunately, we have been unable to obtain further blood samples from the current propositus and his family, nor can we be certain of the length of time the current propositus had the transient Inab phenotype with the anti-IFC. It is interesting to note that the anti-IFC reported here was a direct agglutinin that 
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reacted strongly at 4°C but there was also reactivity, albeit weaker, at IAT; however, reactivity was absent when saline was added in place of the AHG reagent. There is precedent for changes in the GI flora stimulating transient antiblood group antibodies: a 20-day old, K-neonate with sepsis caused by the uncommon E. coli variant O125:B15 produced anti-A and anti-K. Both antibodies were IgM and not of maternal origin. Cell-free isolates of these bacteria could inhibit the agglutination caused by these antibodies and thus bacteria were presumed to have been the sensitizing stimulus. When the infection resolved, the antibodies disappeared. 27 Still, the stimulus for developing the current anti-IFC, as in the two previous reports of patients with transient Inab with anti-IFC remains unclear. 21, 22 The patient in the earlier report had been a blood donor for many years before developing this antibody, and no unexpected antibodies had been detected in his serum at the time of his donations. 21 The other patient with transient Inab phenotype had not been previously transfused, but had been pregnant (J. Poole, personal communication, June 2005). 22 The current propositus was a very young male who had also never been transfused. Although we do not have a blood sample from before April 2004, the appearance and subsequent disappearance of the anti-IFC most likely correlates to the presence (and absence) of the corresponding antigen on the patient's RBCs. Anti-IFC is not invariably present in people with the Inab phenotype: a 70-year-old Italian-American individual who, along with his sister, inherited the Inab phenotype did not demonstrate anti-IFC; given that both he and his sister demonstrated this rare phenotype, it is most likely inherited. Thus anti-IFC is not necessarily present in Inab individuals, even those with a genetic etiology to their phenotype. 16 The appearance of anti-IFC was also noted in the original Inab propositus who presented with an anti-IFC; he had received transfusion of fresh-frozen plasma but apparently not RBCs. 14 A common thread linking the first few reports of patients with the Inab phenotype was that these propositi had GI system abnormalities; the original propositus (Inab) had a protein-losing enteropathy, 14 as did a 12-yearold African American boy who almost certainly had the Inab phenotype. 18 Walthers and coworkers 15 reported a third Inab phenotype patient who had Crohn's disease, whereas Daniels reported a Japanese woman with the Inab phenotype who suffered from blood capillary angioma of the small intestine. 18 Although CD55 is known to be expressed on numerous epithelial surfaces including the gut, 28 a causal association between its deficiency and anatomical lesions of the gut has not been established. DAF knock-out mice had heightened susceptibility to dextran sulfate sodium-induced colitis, suggesting its role in protecting the gut from insult. 29 These similarities have to be interpreted in light of the six other Inab phenotype patients, including the two transient Inab patients, 21, 22 who did not demonstrate nor have a history of GI abnormalities. 16, 17, 20 ACKNOWLEDGMENTS MHY thanks Darrell Triulzi, MD, for thoughtful discussion and critical review of the manuscript.
